Corinfar retard sustained release pills 20mg, 50pcs

Composition

1 tablet of prolonged action, coated, contains:

nifedipine 20 mg.

Auxiliary substances:

Lactose monohydrate,

magnesium stearate,

macrogol 6000,

macrogol 35 000,

talc,

potato starch,

methylhydroxypropylcellulose,

polyvidone K 25,

microcrystalline cellulose,

dyes (E 104, E 171).

Pharmacological action

Corinfar retard is a class II selective calcium channel blocker, a dihydropyridine derivative.

Causes antianginal and hypotensive effects.

Relaxes the smooth muscles of blood vessels.

Relieves spasm and dilates the coronary and peripheral arteries.

Reduces peripheral resistance and slightly-myocardial contractility, reduces afterload on the heart and myocardial oxygen demand.

Improves coronary blood flow and post-stenotic circulation in patients with atherosclerotic obstruction.

It does not inhibit the automatism and conduction of the myocardium, and may cause reflex tachycardia.

Indications

-chronic stable angina (tension angina);- Prinzmetal angina pectoris (variant angina pectoris);- arterial hypertension.

Use during pregnancy and lactation

Corinfar retard is contraindicated for use during pregnancy.

Nifedipine is excreted in breast milk.

Data on the effect of nifedipine on an children are not sufficient.

Therefore, if it is necessary to use Corinfar retard during lactation, breastfeeding should be discontinued.

Contraindications

: arterial hypotension (systolic blood pressure below 90 mm Hg);- cardiogenic shock, collapse— – chronic heart failure in the stage of decompensation;- severe aortic stenosis;- unstable angina; – acute myocardial infarction (first 4 weeks);- co-use with rifampicin;- pregnancy (I trimester);- lactation period;- hypersensitivity to nifedipine and other 1,4-dihydropyridine derivatives or to other components of Corinfar.

With caution: mitral valve stenosis, hypertrophic obstructive cardiomyopathy, severe bradycardia or tachycardia, sinus node weakness syndrome, malignant arterial hypertension, hypovolemia, severe cerebral circulatory disorders, myocardial infarction with left ventricular insufficiency, gastrointestinal obstruction, renal and hepatic insufficiency, hemodialysis (due to the risk of arterial hypotension), pregnancy (II and III trimesters), age up to 18 years (efficacy and safety have not been established), concomitant use of beta-blockers, digoxin.

Dosage: Inside after a meal, without chewing and with a sufficient amount of liquid. The dose of Corinfar is selected by the doctor individually in accordance with the severity of the disease and the patient’s sensitivity to the drug. For patients with concomitant severe cerebrovascular diseases and in elderly patients, the dose should be reduced. Simultaneous food intake delays, but does not reduce the absorption of the Active ingredient from the gastrointestinal tract.

Recommended dosage regimen for adults: – Chronic stable and vasospastic angina pectoris: The initial dose is 10 mg (1 tablet) 2-3 times a day. If the clinical effect is not sufficiently pronounced, the dose of the drug is gradually increased to 2 tablets (20 mg) 1-2 times / day. The maximum daily dose is 40 mg (4 tablets/day). – Essential hypertension: The average daily dose is 10 mg (1 tablet) 2-3 times a day.

If the clinical effect is not sufficiently pronounced, it is possible to gradually increase the dose of the drug to 20 mg (2 tablets) 2 times a day. The maximum daily dose is 40 mg (4 tablets/day).

With a 2-fold appointment, the minimum interval between doses of the drug should be at least 4 hours.

The duration of treatment is determined by the attending physician.

Side effects

From the cardiovascular system, tachycardia, arrhythmias, palpitations, peripheral edema (ankles, feet, shins), manifestations of excessive vasodilation (asymptomatic decrease in blood pressure, development or aggravation of heart failure, flushes of blood to the skin of the face, skin hyperemia, a feeling of heat), a pronounced decrease in blood pressure (rarely), syncope. In some patients, especially at the beginning of treatment or with an increase in the dose, angina attacks may occur, and in some cases-the development of myocardial infarction, which requires discontinuation of the drug.

Nervous system disorders: headache, dizziness, general weakness, fatigue, drowsiness. Long-term use of the drug in high doses – paresthesia of the extremities, tremor, extrapyramidal (Parkinsonian) disorders (ataxia, masked face, shuffling gait, tremor of the hands and fingers, difficulty swallowing), depression.

From the digestive system: dyspepsia (nausea, diarrhea or constipation), dry mouth, flatulence, increased appetite. Rarely-gum hyperplasia, which completely disappears after discontinuation of the drug. With prolonged use-impaired liver function (intrahepatic cholestasis, increased transaminase activity).

Musculoskeletal disorders: arthritis, myalgia, joint swelling.

Allergic reactions: rarely-pruritus, urticaria, exanthema, autoimmune hepatitis, photodermatitis, anaphylactic reactions, exfoliative dermatitis.

Hematopoietic disorders: anemia, leukopenia, thrombocytopenia, thrombocytopenic purpura, agranulocytosis.

From the urinary system: increased daily diuresis in the first weeks of use, deterioration of renal function (in patients with renal insufficiency).

Other: rarely-visual impairment (i. e. transient blindness at the maximum concentration of nifedipine in plasma), gynecomastia (in elderly patients, completely disappearing after withdrawal), galactorrhea, hyperglycemia, pulmonary edema, weight gain.

Interaction

With the simultaneous use of Corinfar retard with other antihypertensive drugs, as well as with tricyclic antidepressants, an increase in the hypotensive effect of Corinfar retard is noted.

With simultaneous use of Corinfar retard with nitrates, an increase in the effect of Corinfar retard on blood pressure and heart rate is noted.

With simultaneous use of Corinfar retard with beta-blockers, a sharper drop in blood pressure may occur, in addition, cases of weakening of heart activity have been observed.

With the simultaneous use of Corinfar retard and cimetidine (to a lesser extent ranitidine), the effects of Corinfar retard may increase.

With the simultaneous use of Corinfar retard with quinidine in some cases, a decrease in the concentration of quinidine in blood plasma was noted, and after the withdrawal of Corinfar retard – a sharp increase in the concentration of quinidine in plasma.

When Corinfar retard was co-administered with digoxin and theophylline, changes in the concentration of the latter in blood plasma were observed in some cases.

How to take, course of use and dosage

They are installed individually.

The average dose is 20 mg 2 times / day. If the clinical effect is not sufficiently pronounced, it is possible to gradually increase the dose of Corinfar retard to 40 mg 2 times a day.

The maximum daily dose is 80 mg.

The interval between meals should not be less than 4 hours. When prescribing the drug 2 times / day. the recommended intake interval is approximately 12 hours (morning and evening).

Tablets are taken after a meal, without chewing and with a sufficient amount of liquid.

Overdose

Symptoms: loss of consciousness up to the development of coma, drop in blood pressure, tachycardia or bradycardia, hyperglycemia, metabolic acidosis, hypoxia.

Treatment: artificial vomiting, gastric lavage, symptomatic therapy aimed at maintaining the activity of the cardiovascular system.

Special instructions

Caution should be exercised when prescribing Corinfar retard to patients with severe hypotension (systolic blood pressure less than 90 mm Hg), chronic heart failure in the decompensation phase, as well as elderly patients over the age of 60 years and patients with severe arterial hypertension (due to the high risk of a sharp drop in blood pressure).

Discontinue Corinfar retard gradually, since sudden discontinuation of the drug (especially after long-term treatment) may lead to the development of withdrawal syndrome, which is expressed in a sharp increase in blood pressure or in the development of myocardial ischemia.

When drinking alcohol on the background of Corinthar retard therapy, it is possible to slow down the speed of psychomotor reactions associated with a decrease in blood pressure.

Use in patients with impaired liver function: Patients with impaired liver function Corinfar retard is prescribed only under careful medical supervision, if necessary, dose adjustment should be carried out.

– Use in patients with impaired renal function: Caution should be exercised when prescribing Corinfar retard to patients with irreversible renal insufficiency and hypovolemia who are on hemodialysis (due to the high risk of a sharp drop in blood pressure).

Use in pediatrics The clinical experience of using the drug in children is insufficient.

Influence on the ability to drive vehicles and manage mechanisms: When taking Corinfar retard, especially at the beginning of treatment and when changing the drug, it is possible to slow down the speed of psychomotor reactions associated with a decrease in blood pressure. This should be taken into account by persons engaged in potentially dangerous activities that require increased attention and speed of psychomotor reactions.

Form of production

Coated tablets.

Storage conditions

In a dark place, at a temperature not exceeding 25 °C

Shelf life

5 years

Active ingredient

Nifedipine

Conditions of release from pharmacies

By prescription

Dosage form

long-acting tablets